FDA-cleared profile

Limbus Contour

Limbus AI Inc.

Limbus Contour assists trained radiation oncologists, dosimetrists, and physicists by generating anatomical contours from CT and MR images for radiation-treatment planning. Version 1.8.0 added CT and MR structures, increased the stated RAM requirement to 16 GB, and retained local Windows deployment and file-system DICOM exchange.

Evidence status: each field shows source quality, applicability, and review date. Research pending, information not established in reviewed sources, and vendor documentation pending are distinct outcomes.

Clinical fit

What this tool is for

Start with the authorized purpose, then verify how it fits your service line and reading workflow.

Exact purpose
Limbus Contour assists trained radiation oncologists, dosimetrists, and physicists by generating anatomical contours from CT and MR images for radiation-treatment planning. Version 1.8.0 added CT and MR structures, increased the stated RAM requirement to 16 GB, and retained local Windows deployment and file-system DICOM exchange.
FDA source Exact FDA submission Checked 2026-09-03
Intended users
Trained radiation oncologists, dosimetrists, and medical physicists responsible for reviewing and modifying contours before treatment-planning use.
FDA source Exact FDA submission Checked 2026-09-03
Care setting and population
Radiation-therapy departments in hospitals, clinics, and other qualified treatment-planning facilities.
FDA source Exact FDA submission Checked 2026-09-03
Workflow role
Initial anatomical contour generation before treatment planning
Public source Exact FDA submission Checked 2026-09-03
Required input
DICOM CT or MR image files from supported radiotherapy workflows; the software relies on an external treatment-planning system or DICOM viewer for image display and contour modification.
FDA source Exact FDA submission Checked 2026-09-03
Output and human action
DICOM RT Structure Set files containing generated anatomical contours for import, display, review, modification, and approval in a treatment-planning system or DICOM viewer.
FDA source Exact FDA submission Checked 2026-09-03
Limitations
The device is not intended for digital mammography and generated contours require qualified review. Structure support changed across releases; confirm whether a requested OAR, lymph-node region, or CTV is included in the exact installed labeling.
FDA source Exact FDA submission Checked 2026-09-03

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K241837
FDA source Exact FDA submission Checked 2026-08-31
Modality
Radiotherapy Planning Imaging
FDA source Exact FDA submission Checked 2026-09-03
Anatomy
Multi-region
FDA source Exact FDA submission Checked 2026-09-03
Clearance type
510(k)
FDA source Exact FDA submission Checked 2026-08-31
Decision date
2024-10-09
FDA source Exact FDA submission Checked 2026-08-31
FDA status
FDA-cleared
FDA source Exact FDA submission Checked 2026-08-31

Implementation

Questions for IT, informatics, and operations

Use these fields to structure a vendor demo, security review, and implementation estimate.

Integration
File-system import of DICOM images and export of DICOM RT Structure Sets to treatment-planning systems or DICOM viewers without a required proprietary plug-in.
Public source Exact FDA submission Checked 2026-09-03
Deployment and data flow
Local Windows or Windows Server software using CPU or optional CUDA-capable NVIDIA GPU processing. The current product-family page describes local processing without cloud transfer; macOS support applied to the initial clearance but not the later releases reviewed here.
Public source Exact FDA submission Checked 2026-09-03
Security and privacy
The current vendor page states that processing runs on local clinical computers and that patient data is not transferred to a cloud service. This reduces external data movement but does not establish the full security posture; confirm authentication, audit logs, patching, support access, backup, and incident-response controls.
Vendor supplied Product family Checked 2026-09-03

Request the current security package and contract controls for the proposed deployment.

Training and support
Only trained and qualified radiation-therapy professionals should operate the software and review, correct, and approve its outputs. Local onboarding must include release-specific limitations, failure examples, escalation, and competency documentation.
Public source Exact FDA submission Checked 2026-09-03
Monitoring and change control
Monitor by exact software and model version, anatomy, structure, scanner and protocol, patient position, contrast, unusual or postsurgical anatomy, reviewer role, edit time, rejected outputs, DICOM-transfer failures, downstream plan effects, incidents, recalls, and updates. Revalidate after material workflow or model changes.
Public source Exact FDA submission Checked 2026-09-03

Release and scope verification

Version 1.8.0 added CT and MR structures, increased the stated RAM requirement to 16 GB, and retained local Windows deployment and file-system DICOM exchange. Procurement should map the installed build, modules, models, anatomies, inputs, and outputs to K241837 before acceptance.

exact submission · checked 2026-09-03

Later product-family features are not evidence that an earlier cleared release includes them.

Interoperability acceptance

File-system import of DICOM images and export of DICOM RT Structure Sets to treatment-planning systems or DICOM viewers without a required proprietary plug-in.

exact submission · checked 2026-09-03

Test representative imports, exports, identifiers, orientation, geometry, structure names, units, failure handling, and round trips in the local environment.

Clinical acceptance

Use a signed local test set spanning supported anatomies, scanners, protocols, unusual or postsurgical anatomy, and small or complex structures. Measure edit burden, rejection, downstream plan effects, and reviewer agreement rather than relying only on average overlap metrics.

product family · checked 2026-09-03

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model total annual and per-plan cost against hands-on and elapsed time after review, correction, failed transfers, rework, support, upgrades, downtime, and any effect on plan quality or throughput.

product family · checked 2026-09-03

Vendor time-saving results are scenario inputs, not guaranteed local savings.

Lifecycle monitoring

Monitor by exact software and model version, anatomy, structure, scanner and protocol, patient position, contrast, unusual or postsurgical anatomy, reviewer role, edit time, rejected outputs, DICOM-transfer failures, downstream plan effects, incidents, recalls, and updates. Revalidate after material workflow or model changes.

product family · checked 2026-09-03

Trend failures and edits by exact software version, model, anatomy, scanner, protocol, and site.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version.

Evidence summary
FDA summaries describe automatic-contouring verification and release-specific structure additions; v1.8.0 also summarizes multi-study evidence and training-data governance. Independent studies report meaningful time savings but show dosimetric consequences from unedited contours and structure-dependent failures, supporting mandatory physician review and local acceptance testing.
Public source Exact FDA submission Checked 2026-09-03
Reported sensitivity
Not applicable
Not applicable Not applicable Checked 2026-09-03

Sensitivity is not an applicable primary endpoint for this radiation-planning software. Review structure-, model-, workflow-, and release-specific geometric, clinical-review, dosimetric, and edit-burden evidence instead.

Reported specificity
Not applicable
Not applicable Not applicable Checked 2026-09-03

Specificity is not an applicable primary endpoint for this radiation-planning software. Review structure-, model-, workflow-, and release-specific geometric, clinical-review, dosimetric, and edit-burden evidence instead.

Prospective implementation cases

551 cases

Eligible CNS, head-and-neck, and prostate cases described in the FDA-cited implementation investigation in Limbus Contour testing described in K241837.

Tested version: Limbus Contour v1.8.0

Prospective implementation surveys

203 surveys

Clinical surveys collected in the FDA-cited implementation investigation in Limbus Contour testing described in K241837.

Tested version: Limbus Contour v1.8.0

Reported mean DSC floor

0.9 DSC

Mean DSC described for most evaluated automatic contours in Limbus Contour testing described in K241837.

Tested version: Limbus Contour v1.8.0

Reported mean 95% Hausdorff ceiling

2 mm

Mean 95% Hausdorff distance described for most evaluated automatic contours in Limbus Contour testing described in K241837.

Tested version: Limbus Contour v1.8.0

Prostate-plus-nodes time saved

26 minutes

Time saved to produce clinically acceptable contours in 15 prostate-plus-nodes cases.

Tested version: Limbus Contour v1.6.0

Prostate-only time saved

13 minutes

Time saved to produce clinically acceptable contours in 15 prostate-only cases.

Tested version: Limbus Contour v1.6.0

Reported DSC floor

0.7 DSC

All reported contours exceeded this DSC value in 30-patient v1.6.0 study.

Tested version: Limbus Contour v1.6.0

K241837 FDA performance package for Limbus Contour

Manufacturer automatic-contouring verification and release-specific structure-model validation · Release-specific CT and MR anatomical structure models described in the FDA summary

exact submission · Tested version: Limbus Contour v1.8.0 · Sponsor or vendor study

K241837

Manufacturer evidence submitted for substantial equivalence. Version 1.8.0 added CT and MR structures, increased the stated RAM requirement to 16 GB, and retained local Windows deployment and file-system DICOM exchange.

Clinical evaluation of Limbus for prostate and nodal radiotherapy contouring

Independent clinical timing, geometric, and dosimetric evaluation by three clinical oncologists · 30 prostate radiotherapy patients, half with prostate-only and half with prostate-plus-nodes planning

product family · Tested version: Limbus Contour v1.6.0 · n=30 · 1 site · Independent study

PMID 38627245 · PMCID PMC11135797

Five of 20 plans optimized using unedited AI structures unnecessarily compromised target coverage, reinforcing expert review.

Economics and lifecycle

Budget and ongoing governance

These are common procurement questions; unknown values remain visible until a source supports them.

Pricing and total cost
Not established in reviewed sources
Reviewed sources checked Exact FDA submission Checked 2026-09-03

No public list price for the exact cleared release was found. Obtain a written quote separating license basis, sites or users, enabled modules or models, implementation, interfaces, compute, storage, training, support, upgrades, renewal, and exit costs.

Reimbursement and coding
No separate named-product Medicare payment was identified in the reviewed CMS Radiation Oncology Model material. Evaluate the product within the radiation-therapy planning service line using net staff time after review, plan quality, rework, throughput, implementation cost, and recurring cost.
Public source Not applicable Checked 2026-09-03

No product-specific code

No separate named-product payment identified in reviewed CMS material

Centers for Medicare & Medicaid Services · United States

Build a local total-cost and value model; do not infer reimbursement from FDA clearance.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K241837 by exact submission identifier.
Public source Exact FDA submission Checked 2026-09-03

A zero-result exact-identifier search does not prove that no recall, correction, adverse-event report, or product-family safety signal exists. Maintain ongoing FDA and vendor surveillance.

Buyer worksheet

Open questions to take to the vendor

Open evaluation checklist

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-04Last searched
24Fields reviewed
10Source classes checked
5Unreviewed PubMed leads
0Unreviewed trial leads
0Unreviewed FDA recall leads

Recovered from the prior exact-submission extraction and normalized under the current provenance rules. Exact FDA decision materials, current product-family materials, directly relevant clinical literature, reimbursement context, and exact-identifier recall candidates were reviewed. Pricing, final security architecture, contracted services, enabled modules or models, interoperability, and local acceptance remain organization-specific evidence. Automated exact-name discovery found 5 PubMed and 0 ClinicalTrials.gov candidate records. Candidates require human product and version matching; zero candidates is not evidence that no studies exist. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads remain unpublished until a human confirms the exact product and tested version.

Source classes: fda ai list, fda decision summary, vendor product page, peer reviewed publication, health technology guidance, reimbursement policy, fda device recall, pubmed, clinical trials, openfda device recall

Sources

Source ledger

Sources accessed through 2026-09-03.

Alternatives

Related tools to compare

FDA-cleared K260509

AutoContour (RADAC V5)

Radformation, Inc.

AutoContour Model RADAC V5 assists radiation treatment planners with contouring and reviewing structures in medical images for radiation therapy treatment planning. It produces...

Modality
Radiotherapy Planning Imaging
Anatomy
Multi-region
Decision
2026-03-19
FDA-cleared K253091

ART-Plan+ (v3.1.0)

Therapanacea Sas

ART-Plan+ assists trained radiation-therapy professionals with multimodal image review, registration, contouring, and the release-specific planning functions described in K253091....

Modality
Radiotherapy Planning Imaging
Anatomy
Multi-region
Decision
2025-12-23
FDA-cleared K242748

Oncospace

Oncospace, Inc.

Oncospace supports trained radiation therapy professionals with protocol configuration, machine-learning achievable-dose prediction, planning-objective exchange, and plan review...

Modality
Radiotherapy Planning Imaging
Anatomy
Multi-region
Decision
2025-04-11